Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of MK-8527 in Healthy Adults (Food Effect and Drug-Drug Interactions)
NCT07661108Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of mk-8527 in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Merck & Co. Primary endpoint: Area Under the Concentration Time Curve From Time 0 to Infinity up to 336 hours. Started Jun 2026; status: active, not recruiting.
02
Drugs
mk-8527
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07661108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07661108.